Article
Phase I study of amonafide dosing based on acetylator phenotype.
Cancer research - 15 May 1993
Ratain M J, Mick R, Berezin F, Janisch L, Schilsky R L, Vogelzang N J, Lane L B
Abstract excerpt
Amonafide is extensively metabolized, including N-acetylation to an active metabolite. Prior studies have demonstrated that patients who are fast acetylators of amonafide (and other drugs) have increased toxicity at standard doses of amonafide. The primary objective of this study was to define the recommended phase II dose of amonafide separately for slow and fast acetylators. Twenty-six patients with advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.